LMPTP inhibitor 23 is primarily used in research focused on understanding and treating metabolic disorders, particularly those related to insulin resistance and type 2 diabetes. By targeting low molecular weight protein tyrosine phosphatase (LMPTP), it helps regulate insulin signaling pathways, improving glucose uptake in cells. This makes it a potential candidate for developing therapies to manage diabetes and related metabolic conditions. Additionally, it is studied for its role in modulating cellular processes that could influence obesity and other insulin-related diseases. Its application is largely confined to preclinical studies, where it aids in exploring the molecular mechanisms of metabolic regulation.